-
1دورية أكاديمية
المؤلفون: Evangelia Vlachou, Burles Avner Johnson, David McConkey, Yuezhou Jing, Andres Matoso, Noah M. Hahn, Jean Hoffman-Censits
المصدر: Frontiers in Oncology, Vol 14 (2024)
مصطلحات موضوعية: advanced/metastatic urothelial cancer, bladder cancer, cutaneous adverse events, disease response, enfortumab vedotin (EV), overall survival (OS), Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
وصف الملف: electronic resource
العلاقة: https://www.frontiersin.org/articles/10.3389/fonc.2024.1377842/fullTest; https://doaj.org/toc/2234-943XTest
-
2دورية أكاديمية
المؤلفون: Bożena Sikora-Kupis, Piotr Domański, Weronika Fortuniak, Barbara Kruczyk, Szymon Staneta, Mateusz Piętak, Anna Mydlak, Tomasz Demkow, Paulina Dumnicka, Jakub Kucharz
المصدر: Contemporary Oncology, Vol 27, Iss 4, Pp 224-229 (2024)
مصطلحات موضوعية: advanced urothelial cancer, enfortumab vedotin (ev), antibody-drug conjugates (adc), toxicity, Medicine
وصف الملف: electronic resource
العلاقة: https://www.termedia.pl/First-experience-in-treating-advanced-urothelial-cancer-withTest-enfortumab-vedotin-Single-centre-retrospective-study-of-patients-qualified-for-a-rescue-access-procedure,3,52310,1,1.html; https://doaj.org/toc/1428-2526Test; https://doaj.org/toc/1897-4309Test
-
3دورية أكاديمية
المؤلفون: Vlachou, Evangelia, Johnson, Burles Avner, McConkey, David, Jing, Yuezhou, Matoso, Andres, Hahn, Noah M, Hoffman-Censits, Jean
المصدر: Front Oncol ; ISSN:2234-943X ; Volume:14
مصطلحات موضوعية: advanced/metastatic urothelial cancer, bladder cancer, cutaneous adverse events, disease response, enfortumab vedotin (EV), overall survival (OS), progression-free survival (PFS), skin toxicity
العلاقة: https://doi.org/10.3389/fonc.2024.1377842Test; https://pubmed.ncbi.nlm.nih.gov/38933451Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199536Test/
الإتاحة: https://doi.org/10.3389/fonc.2024.1377842Test
https://pubmed.ncbi.nlm.nih.gov/38933451Test
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11199536Test/ -
4دورية أكاديمية
المؤلفون: Alvin Jun Xing Lee, Jasmin Viktoria Waterhouse, Mark Linch
المصدر: European Medical Journal, Vol 5, Iss 4, Pp 74-86 (2020)
مصطلحات موضوعية: antibody-drug conjugates (adc), bispecific antibodies, bladder cancer, enfortumab vedotin (ev), fibroblast growth factor receptor (fgfr), immunotherapy, nectin-4, targeted therapies, urothelial cancer, Medicine
وصف الملف: electronic resource